These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21138874)

  • 21. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
    Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
    Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
    Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
    Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer.
    Heckman MG; Parker AS; Wu KJ; Hilton TW; Ko SJ; Pisansky TM; Schild SE; Khor LY; Hammond EH; Pollack A; Buskirk SJ
    Prostate; 2012 Dec; 72(16):1757-66. PubMed ID: 22513981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays.
    Ananthanarayanan V; Deaton RJ; Amatya A; Macias V; Luther E; Kajdacsy-Balla A; Gann PH
    Hum Pathol; 2011 Jun; 42(6):873-81. PubMed ID: 21292307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy?
    Raj GV; Brashears JH; Anand A; Paulson DF; Polascik TJ
    Urology; 2005 Feb; 65(2):332-6. PubMed ID: 15708048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer.
    Wang XL; Wang YY; He HD; Xie X; Yu ZJ; Pan YM
    Cancer Biomark; 2015; 15(6):799-805. PubMed ID: 26406405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program.
    Varkarakis J; Pinggera GM; Sebe P; Berger A; Bartsch G; Horninger W
    Urology; 2004 Feb; 63(2):337-41. PubMed ID: 14972485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.
    Karam JA; Lotan Y; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF
    Prostate; 2007 May; 67(6):614-22. PubMed ID: 17299799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
    Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
    J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.
    Cheng L; Koch MO; Juliar BE; Daggy JK; Foster RS; Bihrle R; Gardner TA
    J Clin Oncol; 2005 May; 23(13):2911-7. PubMed ID: 15860849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome.
    Zietman AL; Edelstein RA; Coen JJ; Babayan RK; Krane RJ
    Urology; 1994 Jun; 43(6):828-33. PubMed ID: 7515206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence.
    Velasco A; Hewitt SM; Albert PS; Hossein M; Rosenberg H; Martinez C; Sagalowsky AI; McConnell JD; Marston W; Leach FS
    Cancer; 2002 Feb; 94(3):690-9. PubMed ID: 11857301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions.
    Nelson CP; Dunn RL; Wei JT; Rubin MA; Montie JE; Sanda MG
    Urol Oncol; 2003; 21(3):213-8. PubMed ID: 12810209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma.
    Pérez-Martínez FC; Alonso V; Sarasa JL; Manzarbeitia F; Vela-Navarrete R; Calahorra FJ; Esbrit P
    Histol Histopathol; 2008 Jun; 23(6):709-15. PubMed ID: 18366009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD147 expression predicts biochemical recurrence after prostatectomy independent of histologic and pathologic features.
    Bauman TM; Ewald JA; Huang W; Ricke WA
    BMC Cancer; 2015 Jul; 15():549. PubMed ID: 26209327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.
    Armstrong AJ; Healy P; Halabi S; Vollmer R; Lark A; Kemeny G; Ware K; Freedland SJ
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):40-5. PubMed ID: 26458958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.